Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at Mizuho

Mizuho upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) to a hold rating in a report released on Wednesday,Zacks.com reports.

Several other brokerages have also recently issued reports on TNDM. Citigroup cut Tandem Diabetes Care from a “buy” rating to a “neutral” rating and dropped their target price for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Robert W. Baird dropped their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a report on Thursday, February 27th. The Goldman Sachs Group cut their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $63.00 target price on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Finally, Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and a consensus target price of $43.88.

Tandem Diabetes Care Trading Up 0.1 %

Shares of Tandem Diabetes Care stock opened at $17.06 on Wednesday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock’s 50 day simple moving average is $23.62 and its 200-day simple moving average is $30.91. The stock has a market cap of $1.13 billion, a P/E ratio of -8.84 and a beta of 1.52. Tandem Diabetes Care has a 1-year low of $15.75 and a 1-year high of $53.69.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Tandem Diabetes Care

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company’s stock valued at $267,989,000 after acquiring an additional 77,451 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its position in Tandem Diabetes Care by 14.1% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company’s stock valued at $98,108,000 after purchasing an additional 337,026 shares in the last quarter. State Street Corp raised its position in Tandem Diabetes Care by 3.2% in the 3rd quarter. State Street Corp now owns 2,655,736 shares of the medical device company’s stock valued at $112,630,000 after purchasing an additional 83,172 shares in the last quarter. GW&K Investment Management LLC boosted its stake in shares of Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after buying an additional 323,674 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Tandem Diabetes Care by 189.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company’s stock worth $59,830,000 after buying an additional 1,086,337 shares in the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.